A phase 1 study of CD38 CAR-T to treat patients with Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs CAR-T cell therapies (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- 07 Feb 2018 New trial record
- 05 Feb 2018 According to a Sorrento Therapeutics media release, IND submission is for the drug is anticipated in 1Q2018 and the first patient treatment is expected by mid 2018. Study may complete within 12 months after initiation.